一种新型口服选择性雄激素受体调节药enobosarm在雄激素受体阳性、雌激素受体阳性和HER2阴性晚期乳腺癌中的活性和安全性(研究G200802):一项随机、开放标签、多中心、多国、平行设计的2期试验

Activity and safety of enobosarm,a novel,oral,selective an-drogen receptor modulator,in androgen receptor-positive,oestrogen receptor-positive,and HER2-negative ad-vanced breast cancer(Study G200802):A randomised,open-label,multicentre,multinational,parall